Axsome Therapeutics (AXSM) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05464T1043

Depression, Sleep, Migraine, Alzheimer's, Narcolepsy, Fibromyalgia

Axsome Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative treatments for central nervous system (CNS) disorders in the United States. Their current product portfolio includes Auvelity, a medication that treats major depressive disorder, and Sunosi, which helps patients with narcolepsy or obstructive sleep apnea overcome excessive daytime sleepiness.

The company is also actively developing several promising therapies, including AXS-05, which is in Phase III clinical trials to treat Alzheimer's disease agitation and has shown potential in helping people quit smoking. Another promising candidate is AXS-07, which has completed Phase III trials for the acute treatment of migraine. Additionally, AXS-12 is in Phase III trials to treat narcolepsy, while AXS-14 has completed Phase III trials for the treatment of fibromyalgia and other conditions.

Axsome Therapeutics is also exploring the potential of solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed Phase 2 trials for treating attention-deficit/hyperactivity disorder and is in Phase 2 trials for major depressive disorder, binge eating disorder, and shift work disorder. The company is collaborating with Duke University to evaluate AXS-05 in smoking cessation.

Founded in 2012, Axsome Therapeutics is headquartered in New York, New York, and is committed to improving the lives of patients with CNS disorders. For more information, visit their website at https://www.axsome.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Axsome Therapeutics (AXSM) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Axsome Therapeutics (AXSM) - Stock Price & Dividends

AXSM Stock Overview

Market Cap in USD 3,416m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2015-11-19

AXSM Stock Ratings

Growth 5y 34.8
Fundamental -52.3
Dividend -
Rel. Performance vs Sector -2.71
Analysts 4.63/5
Fair Price Momentum 70.63 USD
Fair Price DCF -

AXSM Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

AXSM Growth Ratios

Growth 12m -13.30%
Growth Correlation 12m 9%
Growth Correlation 3m 8%
CAGR 5y 26.55%
CAGR/Mean DD 5y 0.70
Sharpe Ratio 12m -0.41
Alpha vs SP500 12m -40.67
Beta vs SP500 5y weekly 1.00
ValueRay RSI 72.47
Volatility GJR Garch 1y 48.67%
Price / SMA 50 3.68%
Price / SMA 200 2.1%
Current Volume 917.7k
Average Volume 20d 797.5k

External Links for AXSM Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of AXSM stocks?
As of June 22, 2024, the stock is trading at USD 76.39 with a total of 917,673 shares traded.
Over the past week, the price has changed by +3.75%, over one month by -2.21%, over three months by -5.53% and over the past year by -13.74%.
What are the forecast for AXSM stock price target?
According to ValueRays Forecast Model, AXSM Axsome Therapeutics will be worth about 78.5 in June 2025. The stock is currently trading at 76.39. This means that the stock has a potential upside of +2.74%.
Issuer Forecast Upside
Wallstreet Target Price 124.8 63.4
Analysts Target Price 116.5 52.4
ValueRay Target Price 78.5 2.74